计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| S649076-5mg |
5mg |
期货 ![]() |
| |
| S649076-10mg |
10mg |
期货 ![]() |
| |
| S649076-25mg |
25mg |
期货 ![]() |
| |
| S649076-50mg |
50mg |
期货 ![]() |
|
| 别名 | SCD1抑制剂-3 |
|---|---|
| 规格或纯度 | ≥98% |
| 英文名称 | SCD1 inhibitor-3 |
| 生化机理 | SCD1 抑制剂-3 是一种安全、强效且具有口服活性的 SCD1 抑制剂。SCD1 抑制剂-3 可用于研究肥胖、II 型糖尿病、血脂异常等代谢性疾病,以及皮肤病、痤疮和癌症。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer In Vivo SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 % . SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Lewis rats Dosage: 5 mg/kg Administration: P.o.; 4 hours Result: Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. Animal Model: Lewis rats Dosage: 2~10 mg/kg Administration: P.o.; 4 hours Result: A dose-responsive reduction of plasma triglycerides desaturation index. Form:Solid IC50& Target:SCD1 |
| 纯度 | ≥98% |
| Smiles | O=C(C1=NNC(N2C=NN(CC3=CC=C(F)C=C3)C2=O)=C1)NCC4=CC=CN=C4 |
|---|---|
| 分子量 | 393.37 |
| 溶解性 | DMSO : ≥ 125 mg/mL (317.77 mM) |
|---|